A. Cetuximab B. Ramucirumab C. Trifluridine D. Regorafenib

A. Panitumumab and cetuximab are both epidermal growth factor receptor inhibitors and have similar black box warnings. B. Regorafenib and bevacizumab act by blocking vascular endothelial growth factor activity. C. Cetuximab or panitumumab are NOT options for treating patients with RAS mutations. D. Ziv-aflibercept is indicated for patients with mCRC, in combination with capecitabine plus oxaliplatin, as a third- or fourth-line treatment option.

A. Discussing her preference for how her oral therapy (including supportive care) should be delivered B. Asking her about whether she has a caregiver or support system to help with obtaining and taking the treatment regimen C. Asking her about whether or not she is aware of the difference in financial responsibility for oral therapies versus intravenous therapies depending on her insurance coverage D. Discussing whether the specialty pharmacy will take on denials if the therapy is used off-label

A. Patients receiving this combination treatment are likely to have nausea from given that oxaliplatin is highly emetogenic. B. Bevacizumab plus FOLFOX has a febrile neutropenia risk of 30%, and patients should be counseled on the administration of filgrastim to start 24 hours after chemotherapy for primary febrile neutropenia prophylaxis. C. Oxaliplatin is known to cause dose-limiting cumulative peripheral neuropathy, so patients should be counseled on the signs and symptoms and report them to the oncologist. D. Oxaliplatin is nephrotoxic and will worsen renal function, so patients should stay hydrated on the days of therapy.